Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Analysts

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has earned a consensus rating of “Buy” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a strong buy recommendation on the company.

A number of research analysts have recently weighed in on IKT shares. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. HC Wainwright raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Friday, December 26th. Cantor Fitzgerald upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Thursday, December 11th. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, December 1st. Finally, Wall Street Zen upgraded shares of Inhibikase Therapeutics to a “sell” rating in a research note on Saturday, December 27th.

Inhibikase Therapeutics Stock Performance

Shares of IKT stock opened at $1.67 on Friday. The company has a market cap of $125.55 million, a P/E ratio of -4.28 and a beta of 0.84. Inhibikase Therapeutics has a 1 year low of $1.33 and a 1 year high of $3.32. The company’s fifty day simple moving average is $1.69.

Inhibikase Therapeutics (NASDAQ:IKT) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.